Isaac Zacharias Biography and Net Worth

Insider of Shockwave Medical

Isaac serves as Shockwave Medical’s Chief Commercial Officer overseeing global commercial activity from December 2018 following his role as GM for Structural Heart and VP of International Sales which began when he joined Shockwave in March 2018. Previously, Isaac served as the Vice President and General Manager for the PCI Guidance business at Boston Scientific where he led a turnaround of this franchise resulting in multiple consecutive years of revenue growth, share gain, and operating income leverage.

Prior to that, Isaac served as VP of New Business Development for Boston Scientific where he negotiated investments and acquisitions totaling more than $1 billion for the Cardiology, Rhythm Management, and Vascular business units. Isaac began his career as an R&D engineer and has held a variety of clinical and marketing roles.

Isaac earned his B.S. and M.S. degrees in Mechanical Engineering from the University of California, Davis.

What is Isaac Zacharias' net worth?: The estimated net worth of Isaac Zacharias is at least $19.02 million as of March 26th, 2024. Mr. Zacharias owns 56,818 shares of Shockwave Medical stock worth more than $19,019,826 as of March 30th. This net worth approximation does not reflect any other assets that Mr. Zacharias may own. Learn More about Isaac Zacharias' net worth.
How do I contact Isaac Zacharias?: The corporate mailing address for Mr. Zacharias and other Shockwave Medical executives is 5403 Betsy Ross Drive, Santa Clara CA, 95054. Shockwave Medical can also be reached via phone at (877) 775-4846 and via email at investors@shockwavemedical.com. Learn More on Isaac Zacharias' contact information.
Has Isaac Zacharias been buying or selling shares of Shockwave Medical?: Isaac Zacharias has not been actively trading shares of Shockwave Medical during the last ninety days. Most recently, Isaac Zacharias sold 4,000 shares of the business's stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $287.67, for a transaction totalling $1,150,680.00. Following the completion of the sale, the insider now directly owns 56,818 shares of the company's stock, valued at $16,344,834.06. Learn More on Isaac Zacharias' trading history.
Who are Shockwave Medical's active insiders?: Shockwave Medical's insider roster includes Colin Cahill (Director), Laura Francis (Director), Douglas Godshall (CEO), Antoine Papiernik (Director), Trinh Phung (VP), Dan Puckett (CFO), Maria Sainz (Director), Frank Watkins (Director), and Isaac Zacharias (Insider). Learn More on Shockwave Medical's active insiders.

Isaac Zacharias Insider Trading History at Shockwave Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/26/2024	Sell	4,000	$287.67	$1,150,680.00	56,818
2/26/2024	Sell	4,000	$260.36	$1,041,440.00	61,372
1/26/2024	Sell	4,000	$224.69	$898,760.00	63,920
12/26/2023	Sell	4,000	$192.50	$770,000.00	41,606
11/27/2023	Sell	4,000	$173.58	$694,320.00	43,868
10/26/2023	Sell	4,000	$210.25	$841,000.00	44,316
9/26/2023	Sell	4,000	$192.12	$768,480.00	47,905
8/25/2023	Sell	4,000	$204.98	$819,920.00	52,446
7/26/2023	Sell	4,000	$268.06	$1,072,240.00	56,678
6/26/2023	Sell	4,000	$291.84	$1,167,360.00	60,678
5/26/2023	Sell	4,000	$277.53	$1,110,120.00	65,223
4/26/2023	Sell	4,000	$289.00	$1,156,000.00	69,454
3/27/2023	Sell	4,000	$215.69	$862,760.00	74,078
2/27/2023	Sell	4,000	$188.51	$754,040.00	64,619
1/26/2023	Sell	4,000	$192.77	$771,080.00	69,021
12/27/2022	Sell	4,000	$209.59	$838,360.00	73,021
11/25/2022	Sell	4,000	$261.82	$1,047,280.00	73,021
10/26/2022	Sell	4,000	$292.44	$1,169,760.00	73,021
9/26/2022	Sell	4,000	$250.07	$1,000,280.00	73,021
8/26/2022	Sell	4,000	$308.25	$1,233,000.00	73,563
7/26/2022	Sell	4,000	$208.28	$833,120.00	74,563
6/27/2022	Sell	4,000	$198.00	$792,000.00	78,563
4/29/2022	Sell	619	$160.36	$99,262.84	65,221
4/26/2022	Sell	3,370	$183.76	$619,271.20	65,840
3/28/2022	Sell	4,000	$188.83	$755,320.00
2/15/2022	Sell	4,000	$149.96	$599,840.00
2/2/2022	Sell	1,617	$153.63	$248,419.71
1/14/2022	Sell	4,000	$175.37	$701,480.00
12/15/2021	Sell	4,000	$172.73	$690,920.00
10/15/2021	Sell	4,000	$194.18	$776,720.00
9/15/2021	Sell	4,000	$220.75	$883,000.00	59,320
8/16/2021	Sell	4,000	$186.97	$747,880.00	60,983
7/15/2021	Sell	4,000	$165.49	$661,960.00	63,420
6/15/2021	Sell	4,000	$188.25	$753,000.00	63,420
5/14/2021	Sell	4,000	$148.18	$592,720.00	54,420
4/15/2021	Sell	4,000	$138.57	$554,280.00	55,050
3/15/2021	Sell	4,000	$114.70	$458,800.00	55,050
2/16/2021	Sell	4,000	$132.39	$529,560.00	62,550
1/15/2021	Sell	4,000	$136.16	$544,640.00	61,282
12/15/2020	Sell	4,000	$92.91	$371,640.00	62,550
11/16/2020	Sell	4,000	$94.17	$376,680.00	62,550
10/15/2020	Sell	4,000	$73.24	$292,960.00	62,550
9/10/2020	Sell	4,000	$66.61	$266,440.00	62,550
7/10/2020	Sell	4,000	$43.19	$172,760.00	38,567
6/10/2020	Sell	4,000	$46.90	$187,600.00	38,567
5/11/2020	Sell	4,000	$41.13	$164,520.00	38,567
4/13/2020	Sell	4,000	$35.34	$141,360.00	39,000
3/10/2020	Sell	4,000	$36.61	$146,440.00	39,000
2/10/2020	Sell	4,000	$44.96	$179,840.00	9,000
1/10/2020	Sell	4,000	$44.78	$179,120.00	9,000
12/10/2019	Sell	4,000	$40.24	$160,960.00	9,000
11/11/2019	Sell	4,000	$35.66	$142,640.00	9,000
10/11/2019	Sell	4,000	$32.68	$130,720.00

See Full Table

Isaac Zacharias Buying and Selling Activity at Shockwave Medical

Shockwave Medical Company Overview

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Today's Range

Now: $334.75

$334.75

50 Day Range

MA: $332.85

$328.87

$334.83

2 Week Range

Now: $334.75

$157.00

$334.90

Volume

N/A

Average Volume

968,088 shs

Market Capitalization

$12.57 billion

P/E Ratio

78.21

Dividend Yield